Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
- Revenue in USD (TTM)7.47m
- Net income in USD-73.06m
- Incorporated2004
- Employees83.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humacyte Inc | 0.00 | -105.70m | 891.94m | 183.00 | -- | 34.11 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 893.85m | 1.80k | 14.65 | 1.79 | 11.99 | 0.9927 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 898.66m | 309.00 | -- | 1.20 | -- | 25.44 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Ocular Therapeutix Inc | 59.84m | -115.27m | 918.49m | 267.00 | -- | 2.25 | -- | 15.35 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 921.58m | 284.00 | -- | 4.53 | -- | 11.39 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 934.67m | 267.00 | -- | -- | -- | 2.26 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Liquidia Corp | 15.97m | -107.69m | 938.74m | 136.00 | -- | 10.87 | -- | 58.79 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| OPKO Health Inc | 799.60m | -252.43m | 947.91m | 3.93k | -- | 0.7567 | -- | 1.19 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Mesoblast Ltd (ADR) | 7.47m | -73.06m | 956.85m | 83.00 | -- | 0.8498 | -- | 128.16 | -1.44 | -1.44 | 0.1388 | 10.03 | 0.0112 | -- | 3.71 | 89,951.80 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
| Innoviva Inc | 311.59m | 181.39m | 970.39m | 112.00 | 7.10 | 1.39 | 4.42 | 3.11 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 983.06m | 284.00 | -- | -- | -- | 23.63 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Perspective Therapeutics Inc | -304.00k | -48.91m | 995.95m | 116.00 | -- | -- | -- | -- | -0.1622 | -0.197 | -0.0009 | -- | -- | -- | -- | -2,620.69 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.03bn | 296.00 | -- | 4.56 | -- | 9.66 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Data as of May 28 2024. Currency figures normalised to Mesoblast Ltd's reporting currency: US Dollar USD
0.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Group One Trading LPas of 31 Mar 2024 | 143.67k | 0.13% |
| Summit X LLCas of 31 Mar 2024 | 139.75k | 0.12% |
| Penbrook Management LLCas of 31 Mar 2024 | 125.18k | 0.11% |
| Regal Funds Management Pty Ltd.as of 31 Mar 2024 | 117.24k | 0.10% |
| Prosperity Wealth Management, Inc.as of 31 Mar 2024 | 77.35k | 0.07% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 62.16k | 0.05% |
| Chase Investment Counsel Corp.as of 31 Mar 2024 | 59.60k | 0.05% |
| Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 59.21k | 0.05% |
| HRT Financial LLCas of 31 Mar 2024 | 57.82k | 0.05% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 57.51k | 0.05% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
